Oral contraceptives give substantial long-term protection against ovarian cancer

January 24, 2008

Use of oral contraceptives during a woman's life-time gives substantial long-term protection against ovarian cancer â€" and the longer they are used, the greater the reduction in risk. These are the conclusions of authors of an Article in this week's edition of The Lancet.

Use of oral contraceptives has long been known to reduce the incidence of ovarian cancer. Because ovarian cancer is not common in young women and the incidence increases with age, the public-health effect of this reduction depends mainly on how the reduced risk persists decades after oral contraceptive use ceases.

Professor Valerie Beral and colleagues from the Collaborative Group on Epidemiological Studies of Ovarian Cancer have brought together 45 epidemiological studies of ovarian cancer to prepare the Article. They studied 23 257 women with ovarian cancer, 7308 (31%) of whom had ever used oral contraceptives; and 87303 women without ovarian cancer, of which 32717 (37%) had ever used oral contraceptives. In women with ovarian cancer, the mean age of diagnosis was 56 years and the median year of diagnosis was 1993. Those that had used contraceptives had done so for an average of 4.4 years in the ovarian cancer group and 5.0 years in the control group.¹

The researchers found that in high income countries, 10 years use of oral contraceptives was estimated to reduce ovarian cancer incidence before age 75 from 12 per 1000 women to 8 per 1000, and mortality from 7 per 1000 women to 5 per 1000. For every 5000 woman-years of oral contraceptive use (eg, if 5000 women used oral contraceptives for one year), about two ovarian cancers and one death from the disease before age 75 are prevented. 2

Further, they found that although oestrogen doses in oral contraceptives have decreased significantly over the years (preparations in the 1960s typically contained more than double the oestrogen dose of preparations in the 1980s), there was no apparent variation in the relative risk of ovarian cancer between women whose oral contraceptive use was during the 1960s, 1970s or 1980s. 3

The risk reduction did not vary substantially by women's ethnicity, education, age her periods began, family history of breast cancer, use of hormone replacement therapy, body-mass index, height, or consumption of alcohol or tobacco. 4

The authors conclude: "Use of oral contraceptives confers long-term protection against ovarian cancer. These findings suggest that oral contraceptives have already prevented some 200000 ovarian cancers and 100000 deaths from the disease, and that over the next few decades the numbers of cancers prevented will rise to at least 30000 per year." 5

In an accompanying Comment, Dr Eduardo Franco, McGill University, Montreal, Quebec, Canada, and Dr Eliane Duarte-Franco, Institut National de Santé Publique de Québec, Montreal, Quebec, Canada, say: "As for the link between oral contraceptives and ovarian cancer, today's collaborative analysis brings unequivocal good news. Women and their health-care providers are once again at a balancing act of judging risks versus benefits."

And a linked Editorial in this week's edition gives a risk-benefit overview of oral contraceptives and asks whether they should be made more widely available to women to protect them from ovarian cancer. It says: "We believe that the case is now convincing. Women deserve the choice to obtain oral contraceptives over-the-counter, removing a huge and unnecessary barrier to a potentially powerful cancer-preventing agent."

It adds: "A strong message about the overall cancer preventing benefits of oral contraceptives would be a positive public-health message, empowering women to decide for themselves about the evidence."
-end-
Notes to editors: ¹ See abstract of full article p303; 2see findings in abstract p303 and results p310; 3see findings in abstract p303 and discussion p312; 4See discussion p311; 5see interpretation in abstract p303 and discussion p312

For Professor Valerie Beral, Cancer Research UK Epidemiology Unit, Oxford University, Oxford, UK, please contact Sally Staples in the Cancer Research UK press office on +44 (0) 20 7061 8313, (out of hours) + (0) 7050 264059 E) pa.valerie.beral@ceu.ox.ac.uk

Dr Eduardo Franco, McGill University, Montreal, Quebec, Canada T) +1 514-975-3237 (but contact by e-mail preferred) E) eduardo.franco@mcgill.ca

The Lancet Press Office, T) +44 (0) 20 7424 4949 E) pressoffice@lancet.comThe paper associated with this release can be found at http://multimedia.thelancet.com/pdf/press/OvarianC.pdf.

Lancet

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.